NASDAQ:IDXG - Interpace Diagnostics Gr Stock Price, Price Target & More

$0.9099 0.00 (0.00 %)
(As of 04/22/2018 08:27 AM ET)
Previous Close$0.9099
Today's Range$0.9010 - $0.93
52-Week Range$0.72 - $3.20
Volume245,151 shs
Average Volume311,500 shs
Market Capitalization$25.36 million
P/E RatioN/A
Dividend YieldN/A
Beta1.74

About Interpace Diagnostics Gr (NASDAQ:IDXG)

Interpace Diagnostics Gr logoInterpace Diagnostics Group, Inc. develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules. The company's customers consist primarily of physicians, hospitals, and clinics. The company was formerly known as PDI, Inc. and changed its name to Interpace Diagnostics Group, Inc. in December 2015. Interpace Diagnostics Group, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

Receive IDXG News and Ratings via Email

Sign-up to receive the latest news and ratings for IDXG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Services
SectorMedical
SymbolNASDAQ:IDXG
CUSIP69329V10
Phone855-776-6419

Debt

Debt-to-Equity RatioN/A
Current Ratio2.45%
Quick Ratio2.45%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$15.90 million
Price / Sales1.59
Cash FlowN/A
Price / CashN/A
Book Value$1.48 per share
Price / Book0.61

Profitability

EPS (Most Recent Fiscal Year)($0.81)
Net Income$-12,210,000.00
Net Margins-76.84%
Return on Equity-37.15%
Return on Assets-24.89%

Miscellaneous

Employees75
Outstanding Shares27,870,000

How to Become a New Pot Stock Millionaire

Interpace Diagnostics Gr (NASDAQ:IDXG) Frequently Asked Questions

What is Interpace Diagnostics Gr's stock symbol?

Interpace Diagnostics Gr trades on the NASDAQ under the ticker symbol "IDXG."

How were Interpace Diagnostics Gr's earnings last quarter?

Interpace Diagnostics Gr (NASDAQ:IDXG) posted its quarterly earnings results on Thursday, August, 10th. The business services provider reported ($0.65) earnings per share for the quarter. The business services provider earned $3.86 million during the quarter. Interpace Diagnostics Gr had a negative return on equity of 37.15% and a negative net margin of 76.84%. View Interpace Diagnostics Gr's Earnings History.

What price target have analysts set for IDXG?

3 Wall Street analysts have issued 1 year target prices for Interpace Diagnostics Gr's stock. Their forecasts range from $3.00 to $4.50. On average, they expect Interpace Diagnostics Gr's stock price to reach $3.50 in the next year. View Analyst Ratings for Interpace Diagnostics Gr.

Who are some of Interpace Diagnostics Gr's key competitors?

Who are Interpace Diagnostics Gr's key executives?

Interpace Diagnostics Gr's management team includes the folowing people:
  • Mr. Jack E. Stover, Chief Exec. Officer, Pres and Director (Age 65)
  • Mr. James E. Early, CFO, Treasurer & Sec. (Age 64)
  • Mr. Thomas John Freeburg, Chief Accounting Officer (Age 50)
  • Mr. Frank Arena, Sr. VP of Established Relationship Sales & Commercial Operations
  • Mr. Gregory Richard, Chief Commercial Officer

Has Interpace Diagnostics Gr been receiving favorable news coverage?

Media coverage about IDXG stock has been trending somewhat positive this week, Accern reports. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Interpace Diagnostics Gr earned a media sentiment score of 0.15 on Accern's scale. They also gave media headlines about the business services provider an impact score of 46.40 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Interpace Diagnostics Gr?

Shares of IDXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Interpace Diagnostics Gr's stock price today?

One share of IDXG stock can currently be purchased for approximately $0.9099.

How big of a company is Interpace Diagnostics Gr?

Interpace Diagnostics Gr has a market capitalization of $25.36 million and generates $15.90 million in revenue each year. The business services provider earns $-12,210,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. Interpace Diagnostics Gr employs 75 workers across the globe.

How can I contact Interpace Diagnostics Gr?

Interpace Diagnostics Gr's mailing address is MORRIS CORPORATE CENTER 1 BUILDING A 300 INTERPACE PARKWAY, PARSIPPANY NJ, 07054. The business services provider can be reached via phone at 855-776-6419 or via email at [email protected]


MarketBeat Community Rating for Interpace Diagnostics Gr (IDXG)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  118 (Vote Outperform)
Underperform Votes:  91 (Vote Underperform)
Total Votes:  209
MarketBeat's community ratings are surveys of what our community members think about Interpace Diagnostics Gr and other stocks. Vote "Outperform" if you believe IDXG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDXG will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Interpace Diagnostics Gr (NASDAQ:IDXG) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Interpace Diagnostics Gr in the last 12 months. Their average twelve-month price target is $3.50, suggesting that the stock has a possible upside of 284.66%. The high price target for IDXG is $4.50 and the low price target for IDXG is $3.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.50$3.50$5.00$5.00
Price Target Upside: 284.66% upside218.18% upside290.63% upside504.23% upside

Interpace Diagnostics Gr (NASDAQ:IDXG) Consensus Price Target History

Price Target History for Interpace Diagnostics Gr (NASDAQ:IDXG)

Interpace Diagnostics Gr (NASDAQ:IDXG) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/6/2018HC WainwrightSet Price TargetBuy$3.00MediumView Rating Details
3/28/2018Maxim GroupSet Price TargetBuy$3.00HighView Rating Details
2/22/2018LaidlawInitiated CoverageBuy -> Buy$4.50HighView Rating Details
(Data available from 4/22/2016 forward)

Earnings

Interpace Diagnostics Gr (NASDAQ:IDXG) Earnings History and Estimates Chart

Earnings by Quarter for Interpace Diagnostics Gr (NASDAQ:IDXG)

Interpace Diagnostics Gr (NASDAQ:IDXG) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.29 EPS
Next Year EPS Consensus Estimate: $-0.19 EPS

Interpace Diagnostics Gr (NASDAQ IDXG) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017Q3 2017($0.15)$4.20 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.65)$3.86 millionViewN/AView Earnings Details
5/15/2017Q1 2017$0.42$3.47 millionViewN/AView Earnings Details
3/29/2017Q4 2016$3.25$3.12 millionViewN/AView Earnings Details
11/18/2016Q3 2016($4.00)$3.32 millionViewN/AView Earnings Details
8/16/2016Q2 2016($1.90)$3.61 millionViewN/AView Earnings Details
5/12/2016Q1 2016($2.30)$3.04 millionViewN/AView Earnings Details
11/12/2015Q3($0.40)($0.31)$32.35 million$36.60 millionViewListenView Earnings Details
8/13/2015Q215($0.46)($0.44)$32.62 million$34.10 millionViewListenView Earnings Details
5/12/2015Q115($0.48)($0.25)$33.20 million$38.30 millionViewListenView Earnings Details
3/3/2015Q414($0.50)($0.27)$140.87 million$28.90 millionViewListenView Earnings Details
11/3/2014Q3($0.19)($0.29)$33.40 million$29.20 millionViewListenView Earnings Details
8/13/2014Q2($0.12)($0.17)$35.60 million$31.60 millionViewListenView Earnings Details
5/7/2014Q1($0.11)($0.11)$39.48 million$32.80 millionViewListenView Earnings Details
2/27/2014Q4($0.11)($0.25)$38.09 million$36.41 millionViewListenView Earnings Details
11/12/2013Q3($0.23)($0.14)$37.98 million$34.26 millionViewListenView Earnings Details
8/5/2013Q2 2013($0.11)($0.06)$35.26 million$37.20 millionViewListenView Earnings Details
5/13/2013Q1 2013($1.10)$1.40$38.02 million$42.92 millionViewN/AView Earnings Details
3/6/2013Q4 2012($0.07)($1.64)$36.90 million$35.60 millionViewListenView Earnings Details
11/5/2012Q3 2012($0.40)($0.60)ViewN/AView Earnings Details
8/13/2012Q2 2012($0.70)($0.27)ViewN/AView Earnings Details
5/14/2012Q1 2012$0.20($0.21)ViewN/AView Earnings Details
3/7/2012Q4 2011($0.40)($0.01)ViewN/AView Earnings Details
11/9/2011Q3 2011($0.60)($0.13)ViewN/AView Earnings Details
8/8/2011Q2 2011($1.10)($0.61)ViewN/AView Earnings Details
5/3/2011Q1 2011($0.90)($0.37)ViewN/AView Earnings Details
3/21/2011Q4 2010$0.20($1.17)ViewN/AView Earnings Details
11/3/2010Q3 2010($1.10)$0.28ViewN/AView Earnings Details
8/4/2010Q2 2010($2.00)($0.62)ViewN/AView Earnings Details
5/6/2010Q1 2010($0.90)($1.19)ViewN/AView Earnings Details
3/4/2010Q4 2009($1.80)($0.99)ViewN/AView Earnings Details
11/5/2009Q3 2009($3.50)($3.21)ViewN/AView Earnings Details
8/5/2009Q2 2009($4.00)($3.40)ViewN/AView Earnings Details
5/6/2009Q1 2009($4.00)ViewN/AView Earnings Details
3/11/2009Q4 2008($7.00)($12.03)ViewN/AView Earnings Details
11/6/2008Q3 2008($6.42)ViewN/AView Earnings Details
8/6/2008Q2 2008($5.30)ViewN/AView Earnings Details
5/8/2008Q1 2008($1.70)($0.76)ViewN/AView Earnings Details
3/12/2008Q4 2007($1.09)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Interpace Diagnostics Gr (NASDAQ:IDXG) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Interpace Diagnostics Gr (NASDAQ IDXG) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.70%
Institutional Ownership Percentage: 13.11%
Insider Trading History for Interpace Diagnostics Gr (NASDAQ:IDXG)
Institutional Ownership by Quarter for Interpace Diagnostics Gr (NASDAQ:IDXG)

Interpace Diagnostics Gr (NASDAQ IDXG) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/25/2014Graham G MiaoCFOBuy22,000$1.65$36,300.00View SEC Filing  
11/10/2014Nancy LurkerCEOBuy49,000$1.75$85,750.00View SEC Filing  
11/7/2014Gerald R Melillo JrInsiderBuy5,000$1.58$7,900.00View SEC Filing  
11/7/2014Jeffrey Edward SmithVPBuy200,000$1.75$350,000.00View SEC Filing  
11/6/2014Nancy LurkerCEOBuy57,000$1.74$99,180.00View SEC Filing  
11/5/2014Gerald P BelleDirectorBuy57,300$1.71$97,983.00View SEC Filing  
11/18/2013Gerald BelleDirectorBuy20,400$5.21$106,284.0084,357View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Interpace Diagnostics Gr (NASDAQ IDXG) News Headlines

Source:
DateHeadline
 Interpace Diagnostics Gr (IDXG) Given Average Recommendation of "Strong Buy" by Brokerages Interpace Diagnostics Gr (IDXG) Given Average Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - April 22 at 3:12 AM
Interpace Diagnostics Gr (IDXG) PT Set at $3.00 by HC WainwrightInterpace Diagnostics Gr (IDXG) PT Set at $3.00 by HC Wainwright
www.americanbankingnews.com - April 6 at 11:06 AM
Interpace Diagnostics Gr (IDXG) Downgraded to "Strong Sell" at ValuEngineInterpace Diagnostics Gr (IDXG) Downgraded to "Strong Sell" at ValuEngine
www.americanbankingnews.com - April 3 at 1:52 PM
Active-Investors: Free Research Report as Verisks Quarterly Revenue Jumped 12.7%; Adjusted EPS Soared 67.5%Active-Investors: Free Research Report as Verisk's Quarterly Revenue Jumped 12.7%; Adjusted EPS Soared 67.5%
www.finanznachrichten.de - April 2 at 8:30 AM
Free Research Report as Verisk’s Quarterly Revenue Jumped 12.7%; Adjusted EPS Soared 67.5%Free Research Report as Verisk’s Quarterly Revenue Jumped 12.7%; Adjusted EPS Soared 67.5%
finance.yahoo.com - April 2 at 8:30 AM
 Interpace Diagnostics Gr (IDXG) Receives Average Rating of "Strong Buy" from Brokerages Interpace Diagnostics Gr (IDXG) Receives Average Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - March 31 at 3:18 PM
Acupath to promote Interpace thyroid testsAcupath to promote Interpace thyroid tests
seekingalpha.com - March 28 at 5:23 PM
Interpace Diagnostics Gr (IDXG) Given a $3.00 Price Target by Maxim Group AnalystsInterpace Diagnostics Gr (IDXG) Given a $3.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - March 28 at 2:04 PM
Interpace Diagnostics Gr (IDXG) Upgraded by ValuEngine to "Sell"Interpace Diagnostics Gr (IDXG) Upgraded by ValuEngine to "Sell"
www.americanbankingnews.com - March 25 at 5:22 PM
Interpace Diagnostics Announces Expansion of LabCorp National AgreementInterpace Diagnostics Announces Expansion of LabCorp National Agreement
finance.yahoo.com - March 20 at 8:21 AM
Interpace Diagnostics Group (IDXG) PT Set at $3.00 by Maxim GroupInterpace Diagnostics Group (IDXG) PT Set at $3.00 by Maxim Group
www.americanbankingnews.com - March 16 at 8:20 PM
Edited Transcript of IDXG earnings conference call or presentation 15-Mar-18 8:30pm GMTEdited Transcript of IDXG earnings conference call or presentation 15-Mar-18 8:30pm GMT
finance.yahoo.com - March 16 at 6:33 PM
Interpace Diagnostics Groups (IDXG) "Buy" Rating Reiterated at HC WainwrightInterpace Diagnostics Group's (IDXG) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - March 16 at 1:48 PM
Interpace Diagnostics Announces Timing of Earnings Release and ... - GlobeNewswire (press release)Interpace Diagnostics Announces Timing of Earnings Release and ... - GlobeNewswire (press release)
globenewswire.com - March 15 at 8:11 AM
Worldpay (WP) and Interpace Diagnostics Group (IDXG) Critical ContrastWorldpay (WP) and Interpace Diagnostics Group (IDXG) Critical Contrast
www.americanbankingnews.com - March 12 at 9:13 PM
Interpace Diagnostics Announces Additional Coverage of Thyroid Tests - GlobeNewswire (press release)Interpace Diagnostics Announces Additional Coverage of Thyroid Tests - GlobeNewswire (press release)
globenewswire.com - March 10 at 8:17 AM
New Research Coverage Highlights Great Western, Acadia Realty Trust, Interpace Diagnostics Group, Abercrombie & Fitch, United Rentals, and ZIOPHARM Oncology — Consolidated Revenues, Company Growth, and Expectations for 2018New Research Coverage Highlights Great Western, Acadia Realty Trust, Interpace Diagnostics Group, Abercrombie & Fitch, United Rentals, and ZIOPHARM Oncology — Consolidated Revenues, Company Growth, and Expectations for 2018
finance.yahoo.com - March 9 at 8:14 AM
Interpace Diagnostics Group (IDXG) Research Coverage Started at HC WainwrightInterpace Diagnostics Group (IDXG) Research Coverage Started at HC Wainwright
www.americanbankingnews.com - March 8 at 11:40 PM
HC Wainwright Takes Bullish Stance On Interpace Diagnostics ... - BenzingaHC Wainwright Takes Bullish Stance On Interpace Diagnostics ... - Benzinga
www.benzinga.com - March 8 at 6:52 PM
Interpace Diagnostics Announces Additional Coverage of Thyroid TestsInterpace Diagnostics Announces Additional Coverage of Thyroid Tests
finance.yahoo.com - March 8 at 6:52 PM
Interpace Diagnostics Announces Additional Coverage of Thyroid Tests - NasdaqInterpace Diagnostics Announces Additional Coverage of Thyroid Tests - Nasdaq
www.nasdaq.com - March 8 at 8:16 AM
Interpace Diagnostics (IDXG) Announces Additional Coverage of Thyroid Tests - StreetInsider.comInterpace Diagnostics (IDXG) Announces Additional Coverage of Thyroid Tests - StreetInsider.com
www.streetinsider.com - March 8 at 8:16 AM
Comparing Interpace Diagnostics Group (IDXG) and Nelnet (NNI)Comparing Interpace Diagnostics Group (IDXG) and Nelnet (NNI)
www.americanbankingnews.com - March 5 at 1:52 PM
Interpace Diagnostics (IDXG) Says Horizon Blue Cross Blue Shield of New Jersey to Cover its Molecular Thyroid TestsInterpace Diagnostics' (IDXG) Says Horizon Blue Cross Blue Shield of New Jersey to Cover its Molecular Thyroid Tests
www.streetinsider.com - February 27 at 5:58 PM
Interpace Diagnostics (IDXG) Says Horizon Blue Cross Blue Shield of New Jersey to Cover its Molecular Thyroid Tests - StreetInsider.comInterpace Diagnostics' (IDXG) Says Horizon Blue Cross Blue Shield of New Jersey to Cover its Molecular Thyroid Tests - StreetInsider.com
www.streetinsider.com - February 27 at 8:14 AM
Interpace Diagnostics CEO Interviewed on The RedChip Money ... - GlobeNewswire (press release)Interpace Diagnostics' CEO Interviewed on The RedChip Money ... - GlobeNewswire (press release)
globenewswire.com - February 23 at 8:16 AM
Interpace Diagnostics Group (IDXG) Research Coverage Started at LaidlawInterpace Diagnostics Group (IDXG) Research Coverage Started at Laidlaw
www.americanbankingnews.com - February 22 at 3:02 PM
Interpace Diagnostics Group Inc (IDXG) PT Lowered to $3 at Maxim Group - StreetInsider.comInterpace Diagnostics Group Inc (IDXG) PT Lowered to $3 at Maxim Group - StreetInsider.com
www.streetinsider.com - February 16 at 8:14 AM
Interpace Diagnostics Group (IDXG) Given a $3.00 Price Target by Maxim Group AnalystsInterpace Diagnostics Group (IDXG) Given a $3.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - February 14 at 10:40 PM
Interpace Diagnostics to Present Data on Thyroid, Pancreatic, and Lung AssaysInterpace Diagnostics to Present Data on Thyroid, Pancreatic, and Lung Assays
finance.yahoo.com - February 12 at 9:07 AM
Analyzing MAXIMUS (MMS) & Interpace Diagnostics Group (IDXG)Analyzing MAXIMUS (MMS) & Interpace Diagnostics Group (IDXG)
www.americanbankingnews.com - January 26 at 9:06 AM
Interpace Diagnostics to Present at NobleCon14 on January 29Interpace Diagnostics to Present at NobleCon14 on January 29
finance.yahoo.com - January 25 at 9:05 AM
Interpace Diagnostics Recognized as One of the Top 20 Bioinformatics Solutions Providers - GlobeNewswire (press release)Interpace Diagnostics Recognized as One of the Top 20 Bioinformatics Solutions Providers - GlobeNewswire (press release)
globenewswire.com - January 8 at 4:00 PM
What Does Interpace Diagnostics Group Inc’s (NASDAQ:IDXG) Share Price Indicate?What Does Interpace Diagnostics Group Inc’s (NASDAQ:IDXG) Share Price Indicate?
finance.yahoo.com - January 6 at 6:30 AM
Comparing Interpace Diagnostics Group (IDXG) & Lifelock (LOCK)Comparing Interpace Diagnostics Group (IDXG) & Lifelock (LOCK)
www.americanbankingnews.com - December 28 at 7:34 PM
Interpace Diagnostics Announces Agreement with ARUP Laboratories - GlobeNewswire (press release)Interpace Diagnostics Announces Agreement with ARUP Laboratories - GlobeNewswire (press release)
globenewswire.com - December 19 at 3:53 PM
Interpace Diagnostics Group (IDXG) and Willdan Group (WLDN) Financial SurveyInterpace Diagnostics Group (IDXG) and Willdan Group (WLDN) Financial Survey
www.americanbankingnews.com - December 19 at 1:26 AM
Interpace Diagnostics Group, Inc. :IDXG-US: Earnings Analysis: Q3, 2017 By the Numbers : December 18, 2017Interpace Diagnostics Group, Inc. :IDXG-US: Earnings Analysis: Q3, 2017 By the Numbers : December 18, 2017
finance.yahoo.com - December 18 at 11:37 AM
Contrasting Interpace Diagnostics Group (IDXG) & Ritchie Bros. Auctioneers (RBA)Contrasting Interpace Diagnostics Group (IDXG) & Ritchie Bros. Auctioneers (RBA)
www.americanbankingnews.com - November 24 at 3:28 AM
Head-To-Head Analysis: Unifirst Corporation (UNF) versus Interpace Diagnostics Group (IDXG)Head-To-Head Analysis: Unifirst Corporation (UNF) versus Interpace Diagnostics Group (IDXG)
www.americanbankingnews.com - November 18 at 3:37 AM
BRIEF-Interpace Diagnostics says ‍New York State Department Of Health approved its TERT service offeringBRIEF-Interpace Diagnostics says ‍New York State Department Of Health approved its TERT service offering
www.reuters.com - November 17 at 6:40 PM
Interpace Diagnostics Announces New York State Approval of New ProductInterpace Diagnostics Announces New York State Approval of New Product
finance.yahoo.com - November 17 at 5:36 AM
Interpace Diagnostics Group, Inc. (IDXG) Rating Reiterated by Maxim GroupInterpace Diagnostics Group, Inc. (IDXG) Rating Reiterated by Maxim Group
www.americanbankingnews.com - November 14 at 1:14 PM
BRIEF-Interpace Diagnostics says Q3 sales up 27 pctBRIEF-Interpace Diagnostics says Q3 sales up 27 pct
www.reuters.com - November 14 at 12:51 AM
Edited Transcript of IDXG earnings conference call or presentation 13-Nov-17 1:30pm GMTEdited Transcript of IDXG earnings conference call or presentation 13-Nov-17 1:30pm GMT
finance.yahoo.com - November 14 at 12:51 AM
Interpace Diagnostics Groups (IDXG) CEO Jack Stover on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaInterpace Diagnostics Group's (IDXG) CEO Jack Stover on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 13 at 7:49 PM
Interpace Diagnostics Group Reports Third Quarter 2017 Financial Results, Business Progress and Recent AccomplishmentsInterpace Diagnostics Group Reports Third Quarter 2017 Financial Results, Business Progress and Recent Accomplishments
finance.yahoo.com - November 13 at 7:49 PM
Interpace Diagnostics to Host Conference Call and Webcast to Discuss Third Quarter 2017 Financial Results and Business Progress on Monday November 13, 2017Interpace Diagnostics to Host Conference Call and Webcast to Discuss Third Quarter 2017 Financial Results and Business Progress on Monday November 13, 2017
finance.yahoo.com - November 11 at 11:14 AM
Ituran Location and Control (ITRN) & Interpace Diagnostics Group (IDXG) Financial ContrastIturan Location and Control (ITRN) & Interpace Diagnostics Group (IDXG) Financial Contrast
www.americanbankingnews.com - November 7 at 9:36 PM
Recent VRSK NewsRecent VRSK News
www.bloomberg.com - November 2 at 1:52 AM

SEC Filings

Interpace Diagnostics Gr (NASDAQ:IDXG) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Interpace Diagnostics Gr (NASDAQ:IDXG) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Interpace Diagnostics Gr (NASDAQ IDXG) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.